Perspective: What Next?

  • Helmut Lydtin
  • Peter Trenkwalder

Abstract

Despite the plethora of pharmacological, haemodynamic, clinical and toxicological data concerning calcium antagonists many questions remain open: some of significance are analysed here.

Keywords

Ischemia Aspirin Cocaine Bark Verapamil 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blankenhorn DH, Kramsch DM (1989) Reversal of atherosis and sclerosis — the two components of atherosclerosis Circulation 79: 1–7Google Scholar
  2. Cohn PF (1988) Silent myocardial ischemia Ann Int Med 109: 312–317Google Scholar
  3. Dehmer GJ, Popma JJ, Van Den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM (1988) Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids N Engl J Med 319: 733–740Google Scholar
  4. Fondazione Giovanni Lorenzini (1989) 4th International Symposium on Calcium Antagonists, Florence (abstract book)Google Scholar
  5. ISIS-2 (Second International Study of Infarct Survival) (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2: 349–360Google Scholar
  6. Neumayer HH, Wagner K (1987) Calciumantagonisten und Gewebeprotektion Intensivmedizin 24: 149–162Google Scholar
  7. The New York Academy of Sciences (1988) Calcium antagonists — Pharmacology and clinical research Ann NY Acad Sci 522Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Helmut Lydtin
    • 1
  • Peter Trenkwalder
    • 2
  1. 1.Starnberg Regional HospitalUniversity of MunichStarnbergGermany
  2. 2.Department of Internal MedicineStarnberg Regional HospitalStarnbergGermany

Personalised recommendations